196 related articles for article (PubMed ID: 11056241)
1. Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up.
Pierce SJ; Gazvani MR; Farquharson RG
Fertil Steril; 2000 Nov; 74(5):964-8. PubMed ID: 11056241
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis.
Kiilholma P; Tuimala R; Kivinen S; Korhonen M; Hagman E
Fertil Steril; 1995 Nov; 64(5):903-8. PubMed ID: 7589632
[TBL] [Abstract][Full Text] [Related]
3. Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.
DiVasta AD; Feldman HA; Sadler Gallagher J; Stokes NA; Laufer MR; Hornstein MD; Gordon CM
Obstet Gynecol; 2015 Sep; 126(3):617-627. PubMed ID: 26181088
[TBL] [Abstract][Full Text] [Related]
4. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up.
Surrey ES; Hornstein MD
Obstet Gynecol; 2002 May; 99(5 Pt 1):709-19. PubMed ID: 11978277
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone agonist plus "add-back" hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial.
Franke HR; van de Weijer PH; Pennings TM; van der Mooren MJ
Fertil Steril; 2000 Sep; 74(3):534-9. PubMed ID: 10973651
[TBL] [Abstract][Full Text] [Related]
6. [Clinical efficacy and safety of gonadotropin releasing hormone agonist combined with estrogen-dydrogesteronea in treatment of endometriosis].
Long QQ; Zhang SF; Han Y; Chen H; Li XL; Hua KQ; Hu WG
Zhonghua Fu Chan Ke Za Zhi; 2010 Apr; 45(4):247-51. PubMed ID: 20646533
[TBL] [Abstract][Full Text] [Related]
7. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome.
Mitwally MF; Gotlieb L; Casper RF
Menopause; 2002; 9(4):236-41. PubMed ID: 12082359
[TBL] [Abstract][Full Text] [Related]
8. Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis.
Divasta AD; Laufer MR; Gordon CM
J Pediatr Adolesc Gynecol; 2007 Oct; 20(5):293-7. PubMed ID: 17868896
[TBL] [Abstract][Full Text] [Related]
9. Add-back therapy in the treatment of endometriosis: the European experience.
Edmonds DK
Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():10-3. PubMed ID: 8916980
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment.
Paoletti AM; Serra GG; Cagnacci A; Vacca AM; Guerriero S; Solla E; Melis GB
Fertil Steril; 1996 Apr; 65(4):707-10. PubMed ID: 8654625
[TBL] [Abstract][Full Text] [Related]
11. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy.
Surrey ES; Voigt B; Fournet N; Judd HL
Fertil Steril; 1995 Apr; 63(4):747-55. PubMed ID: 7890057
[TBL] [Abstract][Full Text] [Related]
12. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial.
Surrey ES; Judd HL
J Clin Endocrinol Metab; 1992 Aug; 75(2):558-63. PubMed ID: 1386374
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial.
Howell R; Edmonds DK; Dowsett M; Crook D; Lees B; Stevenson JC
Fertil Steril; 1995 Sep; 64(3):474-81. PubMed ID: 7641897
[TBL] [Abstract][Full Text] [Related]
14. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density.
Sagsveen M; Farmer JE; Prentice A; Breeze A
Cochrane Database Syst Rev; 2003; 2003(4):CD001297. PubMed ID: 14583930
[TBL] [Abstract][Full Text] [Related]
15. High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement.
Simberg N; Tiitinen A; Silfvast A; Viinikka L; Ylikorkala O
J Clin Endocrinol Metab; 1996 Feb; 81(2):646-51. PubMed ID: 8636283
[TBL] [Abstract][Full Text] [Related]
16. Extending the treatment boundaries: Zoladex and add-back.
Schlaff WD
Int J Gynaecol Obstet; 1999 Feb; 64 Suppl 1():S25-31. PubMed ID: 10096462
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy.
Soliman AM; Bonafede M; Farr AM; Castelli-Haley J; Winkel C
J Manag Care Spec Pharm; 2016 May; 22(5):573-87. PubMed ID: 27123918
[TBL] [Abstract][Full Text] [Related]
18. [Effects and safety of gonadotrophin-releasing hormone agonist combined with estradiol patch and oral medroxyprogesterone acetate on endometriosis].
Wang YQ; Zhang SF; Chen X; Zhu J; Hua KQ; Hu WG
Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):504-8. PubMed ID: 19957549
[TBL] [Abstract][Full Text] [Related]
19. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study.
Wells M; Sturdee DW; Barlow DH; Ulrich LG; O'Brien K; Campbell MJ; Vessey MP; Bragg AJ
BMJ; 2002 Aug; 325(7358):239. PubMed ID: 12153918
[TBL] [Abstract][Full Text] [Related]
20. Prediction of the change in bone mineral density induced by gonadotropin-releasing hormone agonist treatment for endometriosis.
Matsuo H
Fertil Steril; 2004 Jan; 81(1):149-53. PubMed ID: 14711558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
